PRME - Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359
2025-04-25 10:51:29 ET
Summary
- Initiate Hold on Prime Medicine due to pending Phase 1/2 CGD readout in 2025 and Wilson’s Disease IND filing in 2026, focusing on safety and mechanistic editing.
- Await six-month durability data in 2026 or clear non-dilutive funding before re-rating, given rising R&D spend and cash runway into mid-2026.
- PM359 readout seen as a small catalyst; significant share movement depends on demonstrating lasting infection reduction and stable blood counts.
- The competitive landscape includes Rocket Pharma’s lentiviral RP-L102 and CRISPR Therapeutics’ Cas9-edited HSC trials; PM359’s modular assay development offers lower off-target risk.
Summary
We initiate a Hold rating on Prime Medicine ( PRME ). Our view is that the upcoming Phase 1/2 readout in 2025 for the company's lead candidate, PM359, will serve as a binary catalyst, as it will reveal early safety and efficacy data that could solidify proof of concept for a candidate targeting an indication that has no FDA-approved curative treatment. In our view, the mechanism is novel, and there is no way to predict what the data will show, but if strong, it could improve investor sentiment around Prime as the data would green light further clinical development....
Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359